617 related articles for article (PubMed ID: 26572704)
21. Targeting ARID1A mutations in cancer.
Mullen J; Kato S; Sicklick JK; Kurzrock R
Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
[TBL] [Abstract][Full Text] [Related]
22. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
23. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.
Coatham M; Li X; Karnezis AN; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Blake Gilks C; Huntsman DG; Stewart CJ; Postovit LM; Köbel M; Lee CH
Mod Pathol; 2016 Dec; 29(12):1586-1593. PubMed ID: 27562491
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
25. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.
Samartzis EP; Labidi-Galy SI; Moschetta M; Uccello M; Kalaitzopoulos DR; Perez-Fidalgo JA; Boussios S
Ann Transl Med; 2020 Dec; 8(24):1712. PubMed ID: 33490224
[TBL] [Abstract][Full Text] [Related]
26. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
[TBL] [Abstract][Full Text] [Related]
27. [Is endometriosis a precancerous lesion? Perspectives and clinical implications].
Chene G; Caloone J; Moret S; Le Bail-Carval K; Chabert P; Beaufils E; Mellier G; Lamblin G
Gynecol Obstet Fertil; 2016 Feb; 44(2):106-12. PubMed ID: 26850282
[TBL] [Abstract][Full Text] [Related]
28. Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.
Xing B; Zhang X; Gu X; Xiang L; Wang C; Jin Y
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17529-17541. PubMed ID: 37906351
[TBL] [Abstract][Full Text] [Related]
29. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
30. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
Zhai Y; Kuick R; Tipton C; Wu R; Sessine M; Wang Z; Baker SJ; Fearon ER; Cho KR
J Pathol; 2016 Jan; 238(1):21-30. PubMed ID: 26279473
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
[TBL] [Abstract][Full Text] [Related]
34. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
Lowery WJ; Schildkraut JM; Akushevich L; Bentley R; Marks JR; Huntsman D; Berchuck A
Int J Gynecol Cancer; 2012 Jan; 22(1):9-14. PubMed ID: 22193641
[TBL] [Abstract][Full Text] [Related]
35. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract][Full Text] [Related]
36. SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.
Fukumoto T; Magno E; Zhang R
Mol Cancer Res; 2018 Dec; 16(12):1819-1825. PubMed ID: 30037854
[TBL] [Abstract][Full Text] [Related]
37. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
[TBL] [Abstract][Full Text] [Related]
38. Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers.
Falcone R; Filetti M; Lombardi P; Altamura V; Paroni Sterbini F; Scambia G; Daniele G
Explor Target Antitumor Ther; 2023; 4(4):716-726. PubMed ID: 37711591
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE; Miller A; Soslow RA; Lankes HA; DeLair D; Segura S; Chavan S; Zamarin D; DeBernardo R; Moore K; Moroney J; Shahin M; Thaker PH; Wahner-Hendrickson AE; Aghajanian C
Gynecol Oncol; 2023 Sep; 176():16-24. PubMed ID: 37418832
[TBL] [Abstract][Full Text] [Related]
40. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
Wang Q; Wang L; L Y; Ding X; Liu A
J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
